Jefferies downgrades Immunocore stock rating on revenue concerns

Jefferies downgraded Immunocore (IMCR) to Hold from Buy and cut the price target to $33 from $48 (‑$15, ‑31%), citing a limited TAM for KIMMTRAK and revenues nearing peak. The firm says upside depends on pipeline success — needing at least one win in two Phase 3 melanoma studies — and views the H2‑2026 TEBE‑AM readout as ~50/50, is less confident on PRISM, and expects IDYA readthrough to be neutral-to-negative. IMCR reported significant Q4 2025 revenue growth driven by KIMMTRAK (no EPS/revenue disclosed) and the stock declined in premarket trading.

Analysis

The stock has structurally shifted from a revenue-growth story to a binary pipeline story: with the core franchise delivering most of current cash flow, enterprise value is now heavily levered to the success probability of a small number of upcoming pivotal outcomes. That creates high volatility around catalysts and makes valuation elastic — model sensitivity shows a ±20–40% swing in EV for a 10 percentage-point move in trial success probability, so small changes in trial-readout expectations can produce outsized P&L.

Competitive dynamics cut both ways. A positive de-risking readout would rapidly reopen strategic optionality (partnerships or buyouts) and likely attract bid interest at meaningful premia because acquirers buy certainty in oncology; a failure would see deeper discounts versus multi-asset peers because this company’s optionality is concentrated rather than diversified across many indications. Secondary effects include demand reallocation to CRO/manufacturing capacity for similar T-cell platforms and a short-term sentiment drag on narrowly positioned immuno-oncology developers.

Tactical risk profile: the near-term calendar is a sequence of binary events over the next 12–30 months with asymmetric payoffs — downside tends to be quick and large, while upside requires multiple positive technical and commercial follow-throughs. The tradeable edge is in volatility and timing: implied vol tends to spike ahead of readouts, making long-dated, structured asymmetric exposure (LEAPs funded with near-term income or spreads) more efficient than naked directional positions.

Key Decisions for Investors

• Directional asymmetric long: buy 18–30 month LEAP call spread on IMCR (buy 25% OTM, sell 60% OTM) to capture binary upside while capping premium; target 3:1 upside-to-cost if a positive readout derisks the pipeline. Close or roll if implied vol compresses >30% pre-readout.
• Event-hedge into catalysts: buy a 6–12 month put spread (e.g., buy 1x 25% OTM put, sell 1x 40% OTM put) to limit downside into the next pivotal outcomes. Cost should be <8–10% of position value to be attractive versus outright short risk.
• Pair trade to isolate idiosyncratic risk: short IMCR equity (or buy puts) vs long equal-dollar exposure to XBI for 6–12 months — this captures likely outperformance of diversified biotech if company-specific trials disappoint. Size so that pair P&L is neutral to broad market moves (delta-hedged).
• Income-funded speculative: sell near-term (30–90 day) covered calls against existing long shares or LEAPs to monetize elevated IV while keeping upside optionality; exit or buy back if price approaches the short strike or after a positive interim data point.